Serum Institute to try to supply more doses of COVID-19 vaccine to UK later

Published On 2021-03-20 07:06 GMT | Update On 2021-03-20 07:06 GMT

New Delhi: Serum Institute of India (SII) has said it will try to supply more doses of Oxford-AstraZeneca Covid-19 vaccine to the United Kingdom later, based on the current situation and requirement for the government immunisation programme in India.

The UK's National Health Service has warned of a significant reduction in weekly supplies of vaccines to protect against Covid-19 by the end of this month.

When contacted, a spokesperson for SII said, "Five million doses had been delivered a few weeks ago to the UK and we will try to supply more later, based on the current situation and requirement for the government immunisation programme in India".

Last month, SII CEO Adar Poonawalla had urged other countries to be patient as they wait for the supplies of Covid-19 vaccine, Covishield, as the company has been directed to prioritise the needs of India.

Read also: Serum Institute secures CDSCO panel nod for bridge trial of Novavax Covid-19 vaccine

Apart from making efforts to meet the requirements of India, the vaccine major is also trying its best to balance the needs of the rest of the world, he had said.

"Dear countries and governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best", Poonawalla had said in a tweet.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Serum Institute to try to supply more doses of COVID-19 vaccine to UK later

Similar News

Thermo Fisher Scientific unveils Efficient-Pro Medium (+) Insulin

Novartis, Monte Rosa Therapeutics join hands for Degraders to treat Immune-mediated diseases

ZyVet releases generic treatment for Canine Urinary Incontinence in US

Keeping Medicines Without Licence Amounts to 'Offer for Sale', HC Upholds Chemist's Conviction

Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil

Zydus Foundation Vice Chairperson Meha Patel appointed as Member of CII National Committee on Art & Culture for 2025-26

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

Delhi to form special committee to crush fake medicine racket